Intrexon | XON - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Agenus USD 16.02M 2.85M 2025-12
Alaunos Therapeutics USD 1.07M 215K 2023-06
Amgen USD 657M 4M 2026-03
Anika Therapeutics 179.39M 556.84M 2026-03
Arrowhead Research USD 22.5M 811K 2025-12
AstraZeneca USD 484M 181M 2025-12
Bristol-Myers Squibb USD 411M 21M 2026-03
Gilead Sciences USD 240M 15M 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
Heron Therapeutics USD 600K 100K 2024-12
Incyte USD 569K 13K 2026-03
Intrexon USD 2K 5K 2024-06
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
Ligand Pharmaceuticals USD 1.78M 875K 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
MannKind USD 12.43M 1.44M 2026-03
Merck USD 479M 67M 2026-03
Novartis USD 343M 39M 2026-03
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Roche Holding CHF 304M 7.5M 2025-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Thermo Fisher Scientific USD 354M 11M 2026-03
Veracyte USD 2K 1000 2023-12
Xencor USD 4.7M 2.65M 2026-03